Roche: positive opinion from CHMP for subcutaneous Ocrevus
A final decision on its approval by the European Commission is expected mid-2024. If approved, Ocrevus SC would be the first and only 10-minute injection twice a year for relapsing-remitting (RRMS) and primary-progressive (PPMS) MS in the EU.
The Swiss healthcare group points out that its Ocrevus SC would then represent a new, faster way of administering Ocrevus with an efficacy and safety profile comparable to that of the well-established intravenous infusion.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction